CD4 and tuberculosis: Factors associated with tuberculosis treatment outcome among study participants: a higher percentage of participants who had pulmonary TB (84.9%, p < 0.01), on dolutegravir-based ART (86.6%; p = 0.03), with CD4 T-cell count greater than 500 cells/ml (88.2%; p = 0.05) had favorable TB outcome compared to their counterpart who had extrapulmonary TB, on other ART regimen or with CD4 cell count of 500 and below respectively.